^
    Back
    Association details:
    Biomarker:PIK3CA E542K + HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    NEJM
    Title:

    Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Excerpt:
    Treatment with alpelisib–fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously….Figure 2. Subgroup Analysis of Progression-free Survival in the Cohort with PIK3CA-Mutated Cancer.
    Secondary therapy:
    fulvestrant
    Trial ID:
    SOLAR-1
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Breast Cancer (Auckl).
    Title:

    Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib

    Published date:
    08/29/2021
    Excerpt:
    ...66-year-old woman with HR+, PIK3CA mutation-positive (E542K), breast cancer...After discharge, alpelisib was resumed at a reduced dose of 250 mg daily which was well tolerated. Repeat staging scans after 2 cycles of fulvestrant and alpelisib showed a mixed response with stable diffuse osseous and peritoneal metastatic disease, progression of pleural metastases, and resolution of liver metastasis.
    Secondary therapy:
    fulvestrant
    DOI:
    doi: 10.1177/11782234211037421